Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade
- 1 December 1997
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 30 (6), 1621-1627
- https://doi.org/10.1161/01.hyp.30.6.1621
Abstract
Abstract We have shown previously that angiotensin-converting enzyme (ACE) inhibitors prevent coronary vascular remodeling (medial thickening and perivascular fibrosis) and myocardial remodeling (fibrosis and hypertrophy) in rats induced by long-term inhibition of nitric oxide (NO) synthesis with oral administration of N ω -nitro- l -arginine methyl ester (L-NAME). ACE inhibitors inhibit both the formation of angiotensin II and the catabolism of bradykinin. In this study, we aimed to determine the relative contribution of the latter two mechanisms to the beneficial effects of an ACE inhibitor on structural remodeling. First, we examined the effects of the ACE inhibitor temocapril and the angiotensin II AT 1 subtype receptor antagonist CS-866 on the structural remodeling induced by administering L-NAME for 8 weeks. Temocapril and CS-866 were equally effective in preventing remodeling. Second, we examined whether the effect of temocapril on the remodeling induced by L-NAME was reduced by the bradykinin receptor antagonist HOE140. The latter drug did not alter the beneficial effect of temocapril on remodeling. In conclusion, although species differences must be considered to apply our conclusion to clinical conditions, the present results suggest that the inhibition of angiotensin II activity, mediated via the AT 1 receptors, is responsible for the beneficial effects of an ACE inhibitor in our animal model of coronary vascular and myocardial remodeling induced by the long-term inhibition of NO synthesis.Keywords
This publication has 18 references indexed in Scilit:
- Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats.JCI Insight, 1997
- Improved Survival in Rats Administered NG-Nitro L-Arginine Methyl Ester Due to Converting Enzyme InhibitionJournal of Cardiovascular Pharmacology, 1996
- Chronic Inhibition of Nitric Oxide Synthesis Causes Coronary Microvascular Remodeling in RatsHypertension, 1995
- Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase.JCI Insight, 1995
- The role of nitric oxide and other endothelium-derived vasoactive substances in vascular diseaseProgress in Cardiovascular Diseases, 1995
- Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions.JCI Insight, 1993
- Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension.Hypertension, 1992
- Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase.JCI Insight, 1992
- Endothelium and growth factors in vascular remodeling of hypertension.Hypertension, 1991
- Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity.JCI Insight, 1990